Abdominal Aortic Aneurysm Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies involved by DelveInsight | Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical

“Abdominal Aortic Aneurysm Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Abdominal Aortic Aneurysm Market.

The Abdominal Aortic Aneurysm Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Abdominal Aortic Aneurysm Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Abdominal Aortic Aneurysm treatment therapies with a considerable amount of success over the years. Abdominal Aortic Aneurysm Key players such as – Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical, W. L. Gore & Associates, Inc., Medtronic, MicroPort Scientific Corporation, Artivion, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Lombard Medical, Endologix LLC, Latecba SA, Nectero Medical, Cardiatis, SA, Hangzhou Endonom Medtech Co., Ltd., and others, and others, are developing therapies for the Abdominal Aortic Aneurysm treatment 

• Abdominal Aortic Aneurysm Emerging therapies such as – Ticagrelor, Metformin Glucophage, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated AlturaTM FEVAR Stent Graft, Seta Latecba Stent Grafts, Nectero EAST®, Bifurcated MFM®, and others, and others are expected to have a significant impact on the Abdominal Aortic Aneurysm market in the coming years.   

• In January 2024, Arizona-based Nectro Medical has initiated a Phase II/III trial evaluating the safety and efficacy of its endovascular aneurysm stabilisation treatment (Nectero EAST). Nectero EAST is a single-use, endovascular system made up of a dual-balloon delivery catheter and stabiliser mixture of pentagalloyl glucose (PGG). The PGG, when administered locally, can bind to elastin and collagen to potentially strengthen the aortic wall. Animal studies have shown that PGG can hinder the development of abdominal aortic aneurysm (AAA).

Abdominal Aortic Aneurysm Overview

Abdominal Aortic Aneurysm (AAA) is a localized enlargement of the abdominal aorta such that the diameter is greater than 3 cm or more than 50% larger than usual. It occurs when atherosclerosis or plaque buildup causes the walls of the abdominal aorta to become weak and bulge outward like a balloon.

Get a Free Sample PDF Report to know more about Abdominal Aortic Aneurysm Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/abdominal-aortic-aneurysm-pipeline-insight

Abdominal Aortic Aneurysm Pipeline Therapeutics Assessment

• Abdominal Aortic Aneurysm Assessment by Product Type

• Abdominal Aortic Aneurysm By Stage and Product Type

• Abdominal Aortic Aneurysm Assessment by Route of Administration

• Abdominal Aortic Aneurysm By Stage and Route of Administration

• Abdominal Aortic Aneurysm Assessment by Molecule Type

• Abdominal Aortic Aneurysm by Stage and Molecule Type

DelveInsight’s Abdominal Aortic Aneurysm Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Some of the key companies in the Abdominal Aortic Aneurysm Therapeutics Market include:

Key companies developing therapies for Abdominal Aortic Aneurysm  treatment are – CARDIATIS S.A., CARDINAL HEALTH, INC., COOK MEDICAL, INC., ENDOLOGIX, INC., jotec gmbh, LOMBARD MEDICAL, INC., MEDTRONIC PLC, nano endoluminal sa, TERUMO CORPORATION, W. L. GORE & ASSOCIATES, INC., and others.

Download Sample PDF Report to know more about Abdominal Aortic Aneurysm drugs and therapies

Emerging Abdominal Aortic Aneurysm Drugs and devices Under Different Phases of Clinical Development Include:

• Metformin Glucophage: Merck Serono

• Ticagrelor: AstraZeneca

• Abdominal Aortic Aneurysm Stent Graft System: Lifetech Scientific

• Fenestrated AlturaTM FEVAR Stent Graft: Lombard Medical

• Seta Latecba Stent Grafts: Latecba SA

• Nectero EAST®: Nectero Medical

• Bifurcated MFM®: Cardiatis

Abdominal Aortic Aneurysm Pipeline Analysis:

The Abdominal Aortic Aneurysm pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Abdominal Aortic Aneurysm with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Abdominal Aortic Aneurysm Treatment.

• Abdominal Aortic Aneurysm key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Abdominal Aortic Aneurysm Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Abdominal Aortic Aneurysm market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Abdominal Aortic Aneurysm product details are provided in the report. Download the Abdominal Aortic Aneurysm pipeline report to learn more about the emerging Abdominal Aortic Aneurysm therapies

Scope of Abdominal Aortic Aneurysm Pipeline Drug Insight    

• Coverage: Global

• Key Abdominal Aortic Aneurysm Companies: Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical, W. L. Gore & Associates, Inc., Medtronic, MicroPort Scientific Corporation, Artivion, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Lombard Medical, Endologix LLC, Latecba SA, Nectero Medical, Cardiatis, SA, Hangzhou Endonom Medtech Co., Ltd., and others, and others

• Key Abdominal Aortic Aneurysm Therapies: Ticagrelor, Metformin Glucophage, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated AlturaTM FEVAR Stent Graft, Seta Latecba Stent Grafts, Nectero EAST®, Bifurcated MFM®, and others, and others

• Abdominal Aortic Aneurysm Therapeutic Assessment: Abdominal Aortic Aneurysm current marketed and Abdominal Aortic Aneurysm emerging therapies

• Abdominal Aortic Aneurysm Market Dynamics: Abdominal Aortic Aneurysm market drivers and Abdominal Aortic Aneurysm market barriers 

Request for Sample PDF Report for Abdominal Aortic Aneurysm Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/